These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 4479374)

  • 41. Simulated behavior states: an approach to specificity in psychobiological research.
    Post RM; Goodwin FK
    Biol Psychiatry; 1973 Dec; 7(3):237-54. PubMed ID: 4357567
    [No Abstract]   [Full Text] [Related]  

  • 42. Monoamine metabolites in successive samples of spinal fluid. A comparison between healthy volunteers and patients with multiple sclerosis.
    Andersen O; Johansson BB; Svennerholm L
    Acta Neurol Scand; 1981 Apr; 63(4):247-54. PubMed ID: 6163303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parallel variation of homovanillic acid, 5-hydroxyindoleacetic acid and cyclic adenosine-3, 5-monophosphate in ventricular cerebrospinal fluid of man.
    Inagawa T
    Hiroshima J Med Sci; 1982 Jun; 31(2):117-21. PubMed ID: 6182129
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical, biochemical, and hormonal aspects of treatment with Des-tyr1-gamma-endorphin in schizophrenia.
    Verhoeven WM; van Ree JM; Westenberg HG; Krul JM; Brouwer GJ; Thijssen JH; de Wied D; van Praag HM; Ceulemans DL; Kahn RS
    Psychiatry Res; 1984 Apr; 11(4):329-46. PubMed ID: 6204351
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Haloperidol increases the cerebrospinal fluid concentrations of cyclic GMP in schizophrenic patients.
    Gattaz WF; Cramer H; Beckmann H
    Biol Psychiatry; 1984 Aug; 19(8):1229-35. PubMed ID: 6149769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
    González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
    Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroleptic malignant syndrome-like state in a patient with Down syndrome and basal ganglia calcification.
    Komatsu H; Nishimura A; Okano S; Miyanomae Y; Takeuchi Y; Sawada T
    Brain Dev; 1992 Nov; 14(6):400-3. PubMed ID: 1283506
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biochemical changes associated with drug-produced alterations in motor function and the psyche: a possible underlying mechanism.
    Messiha FS; Larson JW
    Proc West Pharmacol Soc; 1977; 20():297-301. PubMed ID: 896838
    [No Abstract]   [Full Text] [Related]  

  • 50. Delusional versus non-delusional depression: Neurochemical differences.
    Sweeney D; Nelson C; Bowers M; Maas J; Heninger G
    Lancet; 1978 Jul; 2(8080):100-1. PubMed ID: 78263
    [No Abstract]   [Full Text] [Related]  

  • 51. [Comparison of the effects of chlorprothixene and haloperidol on hypothalamic function in patients with paranoid schizophrenia].
    Horodnicki JM; Czekalski S; Jarema M; Kubasiewicz A; Pobocha J; Wdowiak J
    Psychiatr Pol; 1985; 19(3):181-7. PubMed ID: 3913968
    [No Abstract]   [Full Text] [Related]  

  • 52. Antiparkinson drugs in paranoid schizophrenia.
    Cavenar JO; Braasch ER; Sullivan JL
    N C Med J; 1979 May; 40(5):287-8. PubMed ID: 35758
    [No Abstract]   [Full Text] [Related]  

  • 53. [Carbamazepine: an effective adjuvant treatment in the schizophrenias].
    Martín Muñoz JC; Moriñigo Domínguez AV; Mateo Martín I; Guajardo-Fajardo Ibarra I; Noval Lamos D
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1989; 17(4):245-50. PubMed ID: 2678932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychosocial factors and amine systems.
    Rogeness GA
    Psychiatry Res; 1991 May; 37(2):215-7. PubMed ID: 1715090
    [No Abstract]   [Full Text] [Related]  

  • 55. Cerebrospinal fluid concentrations of free GABA in schizophrenia: no changes after haloperidol treatment.
    Gattaz WF; Roberts E; Beckmann H
    J Neural Transm; 1986; 66(1):69-73. PubMed ID: 3734777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of Schizophrenic patients.
    Gattaz WF; Rissler K; Gattaz D; Cramer H
    Psychiatry Res; 1986 Jan; 17(1):1-6. PubMed ID: 2868477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Severe extrapyramidal syndrome in a dog caused by a haloperidol (Serenase) intoxication.
    de Leeuw B; Sangster B
    Tijdschr Diergeneeskd; 1979 Jul; 104(14):suppl 134-7. PubMed ID: 473150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tryptophan therapy for non-ketotic hyperglycinaemia.
    Inoue F; Matsuo S; Yoshioka H; Takeuchi Y; Yamanaka H; Kodo N; Kinugasa A; Sawada T
    J Inherit Metab Dis; 1992; 15(3):399-401. PubMed ID: 1383606
    [No Abstract]   [Full Text] [Related]  

  • 59. Biochemical research into psychosis.
    van Praag HM; Korf J
    Acta Psychiatr Scand; 1975 May; 51(4):268-84. PubMed ID: 238363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increase in human urine homovanillic acid concentration after neuroleptic treatment is the same with or without debrisoquin administration.
    Contreras SA; Maas JW; Seleshi E; Bowden CL
    Arch Gen Psychiatry; 1987 Dec; 44(12):1109-10. PubMed ID: 3689099
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.